Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

NCT05292911 · Completed

Last updated 2026-05-28

This clinical trial tests the safety of ALT-801 in overweight or obese adults, both with and without diabetes, who have non-alcoholic fatty liver disease (NAFLD).

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 64 people

Who can join Ages 18–65 · all sexes

Timeline Started 2022-03 · est. completion 2022-10

Where 13 sites · United States

What this study is testing ClinicalTrials.gov NCT05292911 ↗

Description as written by the study sponsor.

This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).

Treatments tested

ALT-801 also known as Pemvidutide Drug

Injected subcutaneously (SC)
Placebo Other

Injected subcutaneously (SC)

Main thing measured	The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Sponsor	Altimmune, Inc.
Conditions studied	Non-Alcoholic Fatty Liver Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05292911 ↗